|1.||Caruso, Michele: 2 articles (07/2015 - 12/2012)|
|2.||Flygare, John: 1 article (07/2015)|
|3.||Soriano, Robert: 1 article (07/2015)|
|4.||Polson, Andrew G: 1 article (07/2015)|
|5.||Jhunjhunwala, Suchit: 1 article (07/2015)|
|6.||Go, MaryAnn: 1 article (07/2015)|
|7.||Cohen, Robert: 1 article (07/2015)|
|8.||Lau, Jeff: 1 article (07/2015)|
|9.||Zheng, Bing: 1 article (07/2015)|
|10.||Yu, Shang-Fan: 1 article (07/2015)|
12/15/2012 - "The antitumor anthracycline nemorubicin is converted by human liver microsomes to a major metabolite, PNU-159682 (PNU), which was found to be much more potent than its parent drug toward cultured tumor cells and in vivo tumor models. "
02/15/2005 - "We also examined the cytotoxicity and antitumor activity of PNU-159682 using a panel of in vitro-cultured human tumor cell lines and tumor-bearing mice, respectively. "
07/15/2015 - "We used the same MC-vc-PAB linker and antibody in pinatuzumab vedotin but replaced the MMAE with a derivative of PNU-159682 to make anti-CD22-NMS249 and tested it for in vivo efficacy in xenograft tumors resistant to MMAE-based ADCs. "
02/15/2005 - "In addition, PNU-159682 was remarkably more cytotoxic than MMDX and doxorubicin in vitro, and was effective in the two in vivo tumor models tested, i.e., disseminated murine L1210 leukemia and MX-1 human mammary carcinoma xenografts. "
|3.||Breast Neoplasms (Breast Cancer)
|3.||K 76 carboxylic acid
|1.||Heterologous Transplantation (Xenotransplantation)